These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30119908)

  • 21. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia.
    Higashi Y; Turzanski J; Pallis M; Russell NH
    Br J Haematol; 2000 Nov; 111(2):565-9. PubMed ID: 11122104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II Study of CPX-351 Followed by Fludarabine, Cytarabine, and Granulocyte-Colony Stimulating Factor for Children With Relapsed Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
    Cooper TM; Absalon MJ; Alonzo TA; Gerbing RB; Leger KJ; Hirsch BA; Pollard J; Razzouk BI; Aplenc R; Kolb EA
    J Clin Oncol; 2020 Jul; 38(19):2170-2177. PubMed ID: 32401633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
    Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
    BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
    Gergis U; Roboz G; Shore T; Ritchie E; Mayer S; Wissa U; McKenna M; Christos P; Pearse R; Mark T; Scandura J; van Besien K; Feldman E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1040-5. PubMed ID: 23648237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
    Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
    Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of guanine arabinoside and Bcl-2 inhibitor YC137 overcomes the cytarabine resistance in HL-60 leukemia cell line.
    Nishi R; Yamauchi T; Negoro E; Takemura H; Ueda T
    Cancer Sci; 2013 Apr; 104(4):502-7. PubMed ID: 23320492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE
    Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
    Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
    Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
    Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
    Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance of leukemia cells to cytarabine chemotherapy is mediated by bone marrow stroma, involves cell-surface equilibrative nucleoside transporter-1 removal and correlates with patient outcome.
    Macanas-Pirard P; Broekhuizen R; González A; Oyanadel C; Ernst D; García P; Montecinos VP; Court F; Ocqueteau M; Ramirez P; Nervi B
    Oncotarget; 2017 Apr; 8(14):23073-23086. PubMed ID: 28160570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
    J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
    Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
    Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
    Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
    Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
    Asghari H; Lancet J
    Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.
    Vincelette ND; Ding H; Huehls AM; Flatten KS; Kelly RL; Kohorst MA; Webster J; Hess AD; Pratz KW; Karnitz LM; Kaufmann SH
    Sci Rep; 2019 Mar; 9(1):3617. PubMed ID: 30837643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
    Santini V; D'Ippolito G; Bernabei PA; Zoccolante A; Ermini A; Rossi-Ferrini P
    Leuk Res; 1996 Jan; 20(1):37-45. PubMed ID: 8632676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.